Leerink Partners has recently initiated IDEXX Laboratories Inc (IDXX) stock to Outperform rating, as announced on December 2, 2024, according to Finviz. Earlier, on July 25, 2024, BTIG Research had initiated the stock to Buy, setting a price target of $580. Piper Sandler also reduced Neutral rating with a price target of $525. Additionally, Exane BNP Paribas initiated Outperform rating on December 7, 2023, with a target price of $602. Cleveland Research analysts, in their report published on December 4, 2023, also raised Buy rating for IDEXX Laboratories Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
IDEXX Laboratories Inc (IDXX) Stock Trading Recap
On Tuesday, IDEXX Laboratories Inc (IDXX) stock saw a decline, ending the day at $426.69 which represents a decrease of $-9.79 or -2.24% from the prior close of $436.48. The stock opened at $439.81 and touched a low of $426.51 during the day, reaching a high of $439.87. The volume of shares traded was 0.88 million exceeding the average volume of 0.68 million.
Sponsored
IDXX Stock Performance and Moving Averages
In recent trading, IDEXX Laboratories Inc (IDXX) stock price has shown some volatility, fluctuating -3.38% over the last five trades and -7.20% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -9.67%, and it has plunged by -0.19% in the previous three months. Currently, IDXX is trading at -4.42%, -2.38%, and -7.62% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, IDXX, a Healthcare sector stock, is trading -24.11% below its 52-week high but remains 7.07% above its 52-week low. The Average True Range (ATR) (14 days) of 13.42 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
IDEXX Laboratories Inc’s Profitability and Valuation Ratios
IDEXX Laboratories Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 28.93% and a profit margin of 22.78%, with a gross margin of -9.67%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, IDEXX Laboratories Inc’s market capitalization stands at $34.70 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 40.00, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 31.44. Additionally, the Price-to-Sales Ratio is 8.90, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 21.83, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.02% of IDEXX Laboratories Inc (IDXX)’s shares, while financial institutions hold 89.80%.
Notable insider trades include FENNELL GEORGE, Executive Vice President at IDEXX Laboratories Inc (IDXX), who sold 9,986 shares on Feb 10 ’25, at $462.53 each, totaling $4.62 million. On Feb 07 ’25, SZOSTAK M ANNE, Director, sold 3,000 shares for $465.94 each, amounting to $1.40 million. Additionally, on Nov 27 ’24, Vandebroek Sophie V. sold 344 shares at $420.44 each, generating $0.14 million.
